Lack of B and T cell reactivity towards IDH1<sup>R132H</sup> in blood and tumor tissue from LGG patients

Bas Weenink<sup>1</sup> · Mandy van Brakel<sup>2</sup> · Rebecca Wijers<sup>2</sup> · Peter A. E. Sillevis Smitt<sup>1</sup> · Pim J. French<sup>1</sup> · Reno Debets<sup>2</sup>

Abstract

**Purpose** Mutations in the isocitrate dehydrogenase-1 gene (IDH1) occur at high frequency in grade II–III gliomas (LGGs). IDH1 mutations are somatic, missense and heterozygous affecting codon 132 in the catalytic pocket of the enzyme. In LGG, most mutations (90%) result in an arginine to histidine substitution (IDH1<sup>R132H</sup>) providing a neo-epitope that is expressed in all tumor cells. To assess the immunogenic nature of this epitope, and its potential use to develop T cell treatments, we measured IDH1<sup>R132H</sup>-specific B and T cell reactivity in blood and tumor tissue of LGG patients.

**Methods** Sera from IDH1<sup>R132H</sup>-mutated LGG patients (n = 27) were assayed for the presence of a neo-specific antibody response using ELISA. In addition, PBMCs (n = 36) and tumor-infiltrating lymphocytes (TILs, n = 10) were measured for T cell activation markers and IFN-γ production by flow cytometry and ELISA. In some assays, frequencies of CD4 T cells specific for mutated peptide presented by HLA-DR were enriched prior to T cell monitoring assays.

**Results** Despite high sensitivity of our assay, we failed to detect IDH1<sup>R132H</sup>-specific IgG in sera of LGG patients. Similarly, we did not observe CD4 T cell reactivity towards IDH1<sup>R132H</sup> in blood, neither did we observe such reactivity following pre-enrichment of frequencies of IDH1<sup>R132H</sup>-specific CD4 T cells. Finally, we did not detect IDH1<sup>R132H</sup>-specific CD4 T cells among TILs.

**Conclusions** The absence of both humoral and cellular responses in blood and tumors of LGG patients indicates that IDH1<sup>R132H</sup> is not sufficiently immunogenic and devalues its further therapeutic exploitation, at least in the majority of LGG patients.

**Keywords** Glioma · Low-grade · IDH1 · Neoantigen

**Introduction**

Gliomas are the most common primary brain cancers in adults. The WHO currently classifies these tumors based on histological and genetic features into oligodendroglioma, astrocytoma and glioblastoma [1]. Approximately 80% of grade II and III tumors harbor driver mutations in isocitrate dehydrogenase (IDH) 1 or 2 genes and are classified as diffuse low-grade gliomas (LGG). Grade IV glioma are classified as high-grade glioma (HGG) and can be distinguished in either primary (IDH wildtype) or secondary (IDH mutant) gliomas [2, 3]. A subset of LGG will progress to HGG within months, while others remain stable for years [4]. Despite advances in neurosurgery, radiotherapy and chemotherapy, almost all glioma patients ultimately die of the disease and thus novel treatment modalities need to be urgently developed.

Recent clinical studies have indicated vaccine- and T cell-based immune therapies as potentially effective novel treatment options for different cancer types [5–8]. For instance, adoptive T cell therapies (ACTs) targeting CD19 have shown durable remissions in patients with refractory B cell ALL and large B cell lymphoma respectively, which has led to
FDA approvals of these T cell products to treat B cell malignancies [9, 10]. However, reactivity of therapeutic T cells against healthy tissues has resulted in severe toxicities in recent trials for cancer patients [11–13]. This stressed the importance to select tumor antigens as well as their corresponding chimeric antigen receptors (CARs) or T cell receptors (TCRs) to minimize chances of on- or off-target toxicities [6, 14, 15].

Neoantigens constitute a class of tumor antigens that appear to represent ideal targets for adoptive T cell therapy. These antigens arise from tumor-specific mutations that alter amino acid coding sequences, and hence are not present in any healthy tissues. Different studies have already focused on the therapeutic targeting of neoantigens derived from hallmark glioma mutations, for instance the epidermal growth factor receptor (EGFRvIII), histone H3 (H3.3K27M) and isocitrate dehydrogenase 1 (IDH1R132H) [16–20]. The IDH1R132H mutation accounts for the vast majority (~ 90%) of all mutations in IDH1 and results in an arginine to histidine amino acid substitution at codon 132 of this gene [21]. Besides a clear role of this mutant in gliomagenesis through the production of the oncometabolite d-2-hydroxyglutarate [22], the IDH1R132H mutation may provide a unique target for immune therapies as its expression is very frequent, stable and present in all tumor cells [23, 24]. In fact, it has previously been established that IDH1R132H can be presented by HLA-DR, and a spontaneous humoral as well as CD4 T cell response may occur in a subset of glioma patients [20, 25]. In order to develop effective immune therapies targeting IDH1R132H, it is critical to assess the frequency and extent of IDH1R132H-specific immune reactivity in a cohort of LGG patients. In the current study, we therefore set out to determine the presence of humoral and cellular immune responses directed against IDH1R132H, both in peripheral blood and tumor tissue of LGG patients.

Materials and methods

Patients and patient samples

Patients with IDH1R132H-mutated grade II and III glioma were diagnosed at Erasmus University Medical Center (Rotterdam, The Netherlands). PBMCs and sera were prospectively collected from glioma patients (prior to surgery) and from healthy donors. Formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples were routinely collected for diagnostic purposes. For experiments using TILs, we obtained fresh tissue directly from the operating theatre from suspected LGG patients. The IDH1 mutation status of these tissues was determined following resequencing by next generation targeted resequencing or immunohistochemistry [23, 26]. In case of unknown IDH1 mutation status, we performed sanger sequencing on DNA isolated from FFPE tumor tissue samples as described previously [27]. All patients provided written informed consent according to national and local regulations for correlative tissue studies. The study was approved by the institutional ethics committee. Patient characteristics are listed in Supplementary table 1.

HLA-DRB1 typing

HLA-DRB1 typing (low resolution, 2 digit) was performed by Sanquin Diagnostic Services (Amsterdam, the Netherlands) using PCR-SSP on DNA isolated from patient PBMC [28].

Peptides

Supplementary table 2 shows an overview of used human IDH1WT and IDH1R132H peptides, which were reported to trigger IgG and CD4 T cell reactivity [20]. Negative control peptide used for T cell stimulation assays was human myelin oligodendrocyte glycoprotein. Staphylococcus-derived enterotoxin B (SEB) was used as positive control (Sigma-Aldrich, Zwijndrecht, the Netherlands). Peptides were synthesized by Pepscan (Lelystad, the Netherlands).

Anti-IDH1R132H IgG ELISA

Pierce Streptavidin Coated High Sensitivity Plates (ThermoFisher, Landsmeer, the Netherlands) were washed in a HydroFlex microplate washer (Tecan, Giessen, the Netherlands) using PBS/0.05% Tween20 (Sigma-Aldrich). Plates were coated with 3 µM peptide in PBS/0.05% Tween20 for 1 h. Plates were washed and PBS/0.05% Tween20 + 10% FBS was added to each well (1 h) in order to reduce nonspecific antibody binding. Sera from IDH1R132H-mutant glioma patients (1:100) were added for 1 h. Plates were washed again and secondary goat anti-human-HRP antibody (1:1000, PI-3000, Vector, Brunschwig chemie, Amsterdam, the Netherlands) was added for 1 h. Primary mouse anti-human IDH1R132H antibody [Clone: H09, 1:5000, Dianova (Bio-Connect, Huissen, the Netherlands)] was used as positive control, to which end, rabbit anti-mouse-HRP antibody (1:1000, PI-3000, Vector, Brunschwig chemie, Amsterdam, the Netherlands) was added for 1 h. Primary mouse anti-human IDH1R132H antibody (Clone: H09, 1:5000, Dianova (Bio-Connect, Huissen, the Netherlands)) was added as second step. After a final wash step, 3,3′,5,5′-tetrathymethylbenzidine (Sigma-Aldrich) was added and incubated until color developed. Reaction was stopped by addition of 1 M hydrochloric acid, and optical densities (OD) at 450 nm were measured using a Multi-skran Ascent Plate Reader (ThermoFisher). All experiments were performed at room temperature.

 Springer
**PBMCs: isolation, enrichment for peptide-specificity and peptide stimulation**

PBMC were isolated from heparin blood by density-gradient centrifugation using Ficoll-Paque PLUS (Sigma-Aldrich). Viable cells and leukocytes were stained using Tuerk solution (Sigma-Aldrich) and Trypan Blue (ThermoFisher), and microscopically counted. Patient PBMC (2 × 10^6 cells) were stimulated with 17.5 µM IDH1R132H, IDH1wt, MOG, or 1 µg/mL staphylococcus-derived enterotoxin B (SEB, Sigma-Aldrich) in 400 µL Iscove’s Modified Dulbecco’s Medium (IMDM) containing 2% l-glutamine, 1% penicillin and streptomycin, supplemented with 6% allogeneic human serum at 37 °C for 16 h.

In some experiments, effector T cells were co-cultured together with peptide-loaded antigen presenting cells prior to peptide stimulation. HeLa cells stably expressing DR1*01:01 and DRB1*01:01 (DR1 + HeLa) or stably expressing DR1*01:01 and DRB1*04:01 (DR4 + HeLa) (kind gift from prof. Fred Falkenburg, LUMC, The Netherlands) [29] were irradiated and added to 96 well tissue culture treated plates (Sigma-Aldrich, 0.05 × 10^5/well) together with autologous patient PBMC (0.4 × 10^5/well) and 17.5 µM or no peptide in IMDM supplemented with 10 ng/mL IL-7 (200 µL/well). Cells were co-cultured for 3–4 weeks and additional cytokines were added. Day 0: 10 ng/mL IL-7, day 3: 22 ng/mL IL-15, day 6: 100 IU/mL IL-2, day 13: 10 ng/mL IL-7, 1 ng/mL IL-15 and 100 IU/mL IL-2. Cells were split using IMDM containing 360 IU/mL IL-2. Following co-culture, T cells were harvested, washed and assayed (0.2 × 10^6) for their reactivity upon stimulation with peptide-loaded DR1+, DR4+ or non-transduced HeLa cells (0.2 × 10^6) at 37 °C for 16 h.

**TILs: isolation and peptide stimulation**

TIL microcultures were initiated and expanded from tumor fragments as described previously [30]. In short, suspected LGG tissue was freshly obtained, washed with PBS and cut in small pieces. Single tumor fragments were placed in each well of a 24-well tissue culture plate with 2 mL of Roswell Park Memorial Institute (RPMI) 1640 medium containing 2% l-glutamine, 25 mM HEPES, 1% penicillin and streptomycin, supplemented with 6% allogeneic human serum and 1000 IU/mL IL-2 (TIL medium) at 37 °C. After 2 weeks of culture, contents of wells with clearly visible lymphocyte growth were pooled for each LGG. Viable cells and leukocytes were stained using Tuerk solution (Sigma-Aldrich) and Trypan Blue (ThermoFisher), and subsequently microscopically counted. Successful cultures of TILs were verified with CD3 flow cytometry (see “Methods” below). To assay reactivity, TILs (2 × 10^6) were plated with 0.5 × 10^6 target cells (irradiated autologous PBMC pulsed with 17.5 µM IDH1R132H, IDH1wt, no peptide) or 1 µg/mL SEB in 200 µL IMDM containing 2% l-glutamine, 1% penicillin and streptomycin, supplemented with 6% allogeneic human serum at 37 °C for 16 h.

**Statistics**

Statistical analysis was performed using RStudio software and statistical methods used are specified in the figure legends.

**Results**

**No detection of IDH1R132H-specific antibodies in patient serum**

We first aimed to identify humoral responses targeting the R132H neo-epitope. To this end, we have performed ELISA measurements to detect IDH1R132H-specific IgG using sera from LGG patients who harbored the IDH1 mutation (n = 27). Healthy donor sera were included as negative controls (n = 5). Using the experimental setup as depicted in Fig. 1a, we observed that sera of most patients provided ELISA signals comparable to those of negative controls. However, in 3 out of 27 samples (patients 6, 15 and 19), we observed an increased antibody signal towards IDH1R132H peptide (Fig. 1b). Given the fact that both IDH1R132H and scrambled peptides revealed equal signals for these patients, we concluded that the detected antibodies were not specific for the R132H neo-epitope.
(Fig. 1c), these signals were interpreted as non-specific. These findings argue that no IDH1R132H-specific antibodies are present in serum of 27 IDH1R132H-mutant LGG patients.

Next, we screened IDH1R132H-mutant glioma patients’ blood for T cell reactivity against this mutant peptide. For this, PBMCs, that contain a mixture of antigen presenting cells and effector T cells, were derived from 30 LGG patients and
loaded with IDH1\textsuperscript{R132H} peptide or control peptides, and after a short-term stimulation, T cells were assessed for up-regulated surface expression of CD137 and production of IFN-\textgamma, both measures of TCR-mediated activation. As the used IDH1\textsuperscript{R132H} peptide has been reported to be promiscuous with respect to MHC class II, particularly HLA-DR alleles, no pre-selection of LGG patients was performed based on HLA alleles [20]. None of 30 patient PBMC samples stimulated with IDH1\textsuperscript{R132H} peptide showed an increased frequency of CD4 T cells expressing CD137 compared to non-mutated peptide (Fig. 2a). Supplementary Fig. 1 shows the gating strategy used in this experiment. No increased frequency of CD137-positive CD8 T cells was observed in mutant peptide stimulation conditions either (data not shown). With respect to IFN-\textgamma, measured in supernatants from the same samples, again no enhanced responses were observed in IDH1 mutant versus wildtype peptide stimulations (Fig. 2b).

Frequencies of peripheral T cells directed against tumor antigens are generally very low in patients [31, 32]. For instance, frequencies of neoantigen-specific T cells in melanoma have been reported to range from 0.002% to at most 0.4% of PBMCs [33]. To address this challenge, we set up a co-culture system to enrich the frequency of IDH1\textsuperscript{R132H} peptide-specific T cells prior to analyzing peptide reactivity. We have previously shown the feasibility of pre-enrichment of antigen-reactive T cells without loss of T cell specificity [29, 34, 35]. In the current study, we have co-cultured patient PBMC with HeLa cells stably expressing HLA-DR1 or DR4, two alleles that were described to facilitate IDH1\textsuperscript{R132H} peptide-specific T cell responses [20], and loaded with IDH1\textsuperscript{R132H} peptide (Fig. 3a). Following 3–4 co-cultivation cycles, T cells were re-stimulated with peptide-loaded HeLa cells, yet again no consistent effect of mutated peptide versus wild-type peptide towards T cell activation was observed in 6 out of 6 patient samples (Fig. 3b, c). Collectively, when using PBMC from LGG patients who harbor the IDH1 mutant, whether or not pre-enriched for T cell reactivity against mutant IDH1 peptide, we did not observe IDH1\textsuperscript{R132H}-specific CD4 T cell responses.

**No detection of IDH1\textsuperscript{R132H}-specific T cells in tumor tissue**

When compared to blood, the number of mutant-specific T cells may be enriched in IDH1\textsuperscript{R132H} expressing tumor tissue in case an effective T cell response had occurred [36–39], providing a rationale to screen for the presence of IDH1\textsuperscript{R132H}-specific CD4 T cells among TILs. TILs were polyclonally expanded from fresh resection material derived from 10 LGGs (with IDH1 mutation) and were subsequently stimulated with IDH1\textsuperscript{R132H} peptide loaded, irradiated autologous PBMCs. Also using TILs, we were not able to observe changes with respect to CD137 expression and IFN-\textgamma production of CD4 T cells for 10 out of 10 patients (Fig. 4).

**Discussion**

In this study, we focused on detecting the presence of IDH1\textsuperscript{R132H}-specific T and B cell reactivity in IDH1\textsuperscript{R132H}-mutant LGG patients. Detection of immune reactivity against this mutated peptide would warrant and at the same time facilitate the development of immunotherapy towards IDH1\textsuperscript{R132H}+ gliomas. Using various readouts for B

---

**Fig. 2** Blood of LGG patients do not harbor CD4 T cell reactivity against IDH1\textsuperscript{R132H}. PBMCs from patients with IDH1\textsuperscript{R132H}-positive gliomas were directly stimulated with IDH1\textsuperscript{R132H} or IDH1\textsuperscript{WT} peptide for 16 h (n = 30 patients). a Percentage of CD137+ cells within CD4+ T cells. b IFN-\textgamma response of the same T cell populations as in (a). Each dot represents an individual patient sample. MOG, IDH1\textsuperscript{WT}, and IDH1\textsuperscript{R132H} were corrected for the medium values. Medium, no peptide, negative control. SEB, staphylococcus-derived enterotoxin B, positive control. MOG, myelin oligodendrocyte glycoprotein peptide, negative control.
and T cell responses, and using sera (n = 27 patients), PBMC (n = 30) as well as TILs (n = 10), we showed that immune cell populations with reactivity towards mutant IDH1 are not present in the LGG patient samples studied here.

These findings are in contrast to previous observations where Schumacher and colleagues demonstrated humoral and CD4 T cell responses in patients with glioma [20]. In our study we cannot exclude that we were not able to detect mutant-specific immune reactivity despite their presence in a subset of LGG patients and this could be due to a number of reasons.

First, levels of IDH1R132H-specific antibodies or frequencies of IDH1R132H-specific CD4 T cells may be below the detection thresholds of assays. For instance, among TILs from (multiple and pooled) IDH1R132H-mutant tumors, the frequency of IDH1R132H-specific CD4 T cells was less than 2% (of CD4+ T cells) after vaccinating mice with mutant peptides [20]. Indeed, the central nervous system is considered to be immune-privileged, e.g. due to limited MHC expression, and consequently elicitation of robust glioma-specific immune responses may be limited [40]. Along this line, suppression of anti-tumor T cell immunity by the oncometabolite 2-hydroxyglutarate has also recently been described in LGG [41], which may further limit local activation of IDH1R132H-specific CD4 T cells. A tentative low frequency of IDH1R132H-specific CD4 T cells was addressed by pre-enrichment of these cells by co-culturing PBMC of IDH1R132H-mutant patients with HeLa cells presenting IDH1R132H. None of the samples showed an IDH1R132H-specific T cell activation response, whether or not CD4 T cells underwent co-culture cycles with IDH1R132H-presenting cells [42, 43]. Although the occurrence of very low frequencies of IDH1R132H-specific T cells cannot be dismissed, and these could be targeted with enrichment protocols using more professional antigen-presenting cells, optimal pMHC bindings [44] or in vivo

![Fig. 3](image.png)

Fig. 3 No CD4 T cell reactivity against IDH1R132H despite long-term pre-culture of CD4 T cells in presence of antigen. a Scheme of co-culture system used to enrich frequencies of mutant-specific T cells. In short, HLA-DR1 or DR4-positive patient PBMC were co-cultured with HLA-DR1 or -DR4 transduced HeLa cells loaded with IDH1R132H peptide or no peptide for 4 weeks. Prior to measurements of T cell activation, T cell populations (n=6 patients) were stimulated with DR1 or DR4-positive HeLa cells loaded with IDH1R132H or IDH1WT peptide for 16 h. b Percentage of CD137+ cells of CD4+ T cells. c IFN-γ response of the same T cell populations used in (b). Each dot represents an individual patient sample. DR1+R132H, DR1+WT, DR4+R132H, DR4+WT were corrected for the medium values. DR1, HeLa cells transduced with DRB1*01:01. DR4, HeLa cells transduced with DRB1*04:01.
vaccinations with IDH1R132H [45], our data do suggest that the immunogenicity of IDH1R132H is low.

Second, the number of patients assayed may have been too small in order to detect a cellular (n = 46; 36 PBMC and 10 TIL samples) or humoral immune response (n = 27). Percentages of patients with antibody or CD4 T cell responses in blood have been reported to be as low as 10% and 16%, respectively [20]. However, even in the case of a population frequency of 10%, there is a 94% chance of detecting at least one positive humoral response, and a 75% chance if the population frequency is 5% (using a cohort of 27 samples). Moreover, when combining the 36 PBMC and 10 TIL samples used to detect T-cell responses against IDH1R132H, there is > 99% or 91% chance of detecting such responses in population frequencies of at least 10% or 5% respectively.

Third, we cannot exclude that IDH1R132H may be presented by specific HLA alleles that are underrepresented in our cohort of tested patients and/or that expression levels of IDH1 are too low to elicit IDH1R132H-specific T-cell responses. Indeed, glioblastomas express IDH1 at higher levels compared to gliomas of lower grade (log2 expression levels of 10.9 ± 0.48 vs. 11.3 ± 0.49, vs. 11.4 ± 0.48 for grade II (n = 24), grade III (n = 85) and grade IV gliomas (n = 159) respectively [46]). However, the relative increase in IDH1 expression with increasing tumor grade is very modest and expression levels of IDH1 are in general relatively high. Moreover, there is no difference between grade III astrocytomas and grade IV glioblastomas 11.4 ± 0.48 vs. 11.4 ± 0.43, p = 0.89).

Taken together, our data does not provide evidence for detectable presence of immune cell reactivity towards IDH1R132H in blood or tumors of LGG patients. We advocate further preclinical studies prior to development and clinical exploitation of T cell treatments directed against IDH1R132H in LGG patients.

Funding This work was not supported by any external funding.

Compliance with ethical standards

Conflict of interest All authors declare no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131:803–820. https://doi.org/10.1007/s00401-016-1545-1

2. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Griffford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yang WK, Rabdan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH, Network TR, Noushmehr H, Iavarone A, Verhaak RG (2016) Molecular profiling reveals biologically discrete subsets
and pathways of progression in diffuse glioma. Cell 164:550–563. https://doi.org/10.1016/j.cell.2015.12.028

3. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kostel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wielmers J, Wienckje JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoA1407279

4. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Leonard A, Nace AK, Dentchev T, Thakkar KT, Lebwohl D, Murphy WJ, Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Drigger EM, Eichmuller SB, Okura J, Sokal MB, Hill DL, Zischka L, Espinosa RJ, Coluccia C, Koo J, Korshunov A, Zentgraf H, Hartmann C, von Deimling A, Wick W, Platten M (2017) K27M-histone 3 variant H3K27M mutation for glioma T cell therapy. J Exp Med 215:141–157. https://doi.org/10.1084/jem.20171046

5. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, Gratawa JW, Stoter G, Oosterwijk E (2006) Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically targeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 24:e20–22. https://doi.org/10.1200/JCO.2006.05.9964

6. Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33:2092–2099. https://doi.org/10.1200/JCO.2014.60.0379

7. Kunert A, Obenaus M, Lamers CHJ, Blankenstein T, Debets R (2017) T-cell receptors for clinical therapy: in vitro assessment of toxicity risk. Clin Cancer Res 23:6012–6020. https://doi.org/10.1158/1078-0432.CCR-17-1012

8. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, Schmitting RJ, Nair SK, Reap EA, Norberg PK, Herndon JE 2nd, Kuan CT, Morgan RA, Rosenberg SA, Johnson LA (2014) EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res 20:972–984. https://doi.org/10.1158/1078-0432.CCR-13-0709

9. Johnson LA, Scholler J, Ohkuri T, Kosaka A, Patel PR, McGittigan SE, Nace AK, Dentchev T, Thekkat P, Loew A, Boesteanu AC, Cogdill AP, Chen T, Fraietta JA, Kloss CC, Posey AD Jr, Engels B, Singh R, Ezzel T, Iamakanti N, Ramones MH, Li N, Zhou L, Plesa G, Seykoura JT, Okada H, June CH, Brogdon JLI, Maus MV (2015) Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma. Sci Transl Med. 7:275ra222. https://doi.org/10.1126/scitranslmed.aad4963

10. Chedda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, Yang X, Carrera DA, Downey KM, Shrivastav S, Liu S, Lin Y, Lagisetti C, Chuntova P, Watchmaker PB, Mueller S, Pollack IF, Rajalingam R, Carcaboso AM, Mann M, Sette A, Garcia KC, Hou Y, Okada H (2018) Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med 215:141–157. https://doi.org/10.1084/jem.20171046

11. Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, Sonner JK, Keil M, von Deimling A, Wick W, Platten M (2017) K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology 6:e1328340. https://doi.org/10.1080/21624012.2017.1328340

12. Schumacher T, Bunse T, Lusch P, Sahm F, Wiestler B, Quandt J, Meier O, Osowski M, Ozen I, Ott M, Keil M, Balss J, Rauschenbach K, Grabowska AK, Vogler I, Diekmann J, Trautwein N, Eichmüller SB, Okun J, Stavenovic S, Riemer AB, Sahin U, Friese MA, Beckhoff P, von Deimling A, Wick W, Platten M (2014) A vaccine targeting modified IDH1 induces antitumour immunity. Nature 512:324–327. https://doi.org/10.1038/nature13387

13. Kloosterhof NK, Bralten LB, Dubbink HJ, French PJ, van den Bent MJ (2011) Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma? Lancet Oncol 12:83–91. https://doi.org/10.1016/S1470-2045(10)70053-X

14. Deng L, White DW, Gross S, Bennett BD, Bittinger MA, Driegers EM, Fantin VR, Jiang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liu LM, Rabirinovitz JD, Cantley LC, Thompson CB, Vandier Heiden MG, Su SM (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–744. https://doi.org/10.1038/nature08617

15. Capper D, Weissett S, Balss J, Habel A, Meyer J, Jager D, Ackermann U, Tessmer C, Korschunov A, Zentgraf H, Hartmann C, von Deimling A (2010) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245–254. https://doi.org/10.1111/j.1750-3639.2009.00352.x

16. Tomczak K, Czerwinska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of
knowledge. Contemp Oncol 19:468–77. https://doi.org/10.5114/wo.2014.47136

25. Bunse L, Schumacher T, Sahn F, Pusch S, Oeen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M (2015) Proximity ligation assay evaluates IDH1R132H presentation in gliomas. J Clin Invest 125:593–606. https://doi.org/10.1172/JCI77780

26. Dubbink HJ, Atmosmedjo PN, Kros JM, French PJ, Sanson M, Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschinger J, Walker PR, Romero PJ, Valmori D, Speiser DE, Dietrich PY (2007) Long-lived antitumor CD8+ lymphocytes for adoptive transfer therapy for melanoma patients. J Immunother 26:332–342

27. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron (2013) HLA typing by sequence-specific primers. Methods Mol Biol 1034:147–159. https://doi.org/10.1007/978-1-62703-493-7_8

28. Bunse M, Passey B (2013) HLA typing by sequence-specific primers. Methods Mol Biol 1034:147–159. https://doi.org/10.1007/978-1-62703-493-7_8

29. Rutten CE, van Luxemburg-Heijs SA, van der Meijden ED, Griffioen M, Oudshoorn M, Willemze R, Falkenburg JH (2010) HLA-DPB1 mismatching results in the generation of a full repertoire of HLA-DPB1–specific CD4+ T cell responses showing immunogenity of all HLA-DPB1 alleles. Biol Blood Marrow Transplant 16:1282–1292. https://doi.org/10.1016/j.bbmt.2010.03.018

30. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26:332–342

31. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron (2013) HLA typing by sequence-specific primers. Methods Mol Biol 1034:147–159. https://doi.org/10.1007/978-1-62703-493-7_8

32. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron (2013) HLA typing by sequence-specific primers. Methods Mol Biol 1034:147–159. https://doi.org/10.1007/978-1-62703-493-7_8

33. Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamakov K, Trebska-McGowan K, Bliskovsky VV, Parkhurst MR, Ankri C, Prickett TD, Crystal JS, Li YF, El-Gamil M, Rosenberg SA, Robbins PF (2015) Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125:3981–3991. https://doi.org/10.1172/JCI72416

34. Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Kros JM, Sillevis Smitt PA, van den Bent MJ, French PJ (2009) Intrinsically malignant melanoma patients before and after vaccination with tumor antigens. J Clin Invest 125:593–606. https://doi.org/10.1172/JCI77780

35. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron (2013) HLA typing by sequence-specific primers. Methods Mol Biol 1034:147–159. https://doi.org/10.1007/978-1-62703-493-7_8

36. Le Gal FA, Widmer VM, Dutot V, Rubio-Godoy V, Schrenzel J, Walker PR, Romero PJ, Valmori D, Speiser DE, Dietrich PY (2007) Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol 127:622–629. https://doi.org/10.3138/jido.5700580

37. Lee KH, Panelli MC, Kim CJ, Riker AI, Bettinotti MP, Roden MM, Fetsch P, Abati A, Rosenberg SA (1998) Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183–4194

38. Panelli MC, Bettinotti MP, Lally K, Ohnmacht GA, Li Y, Robbins P, Riker A, Rosenberg SA, Marincola FM (2000) A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12. J Immunol 164:4382–4392

39. Panelli MC, Riker A, Kammula U, Wang E, Lee KH, Rosenberg SA, Marincola FM (2000) Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases. J Immunol 164:495–504

40. Korn T, Kallies A (2017) T cell responses in the central nervous system. Nat Rev Immunol 17:179–194. https://doi.org/10.1038/nnri.2016.144

41. Bunse L, Pusch S, Bunse T, Sahn F, Sanghvi K, Friedrich M, Alansary D, Sonner JK, Gorynski R, Mallinckrodt R, Mulligan RC, Nadler LM, Hirano N (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13:1857–1867. https://doi.org/10.1158/1078-0432.CCR-06-1905

42. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13:1857–1867. https://doi.org/10.1158/1078-0432.CCR-06-1905

43. Cheung AS, Zhang D, Koshly ST, Mooney DJ (2018) Sca folds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells. Nat Biotechnol 36:160–169. https://doi. org/10.1038/s41597-018-0095-6

44. Dolgor G, Zerovadi E, Rius C, Wall A, Thomas HL, Fuller A, Yeo L, Legut M, Wheeler S, Attai M, Chudakov DM, Choy E, Peakman M, Sewell AK (2018) Optimized peptide-MHC multimer protocols for detection and isolation of autoimmune T-cells. Front Immunol 9:1378. https://doi.org/10.3389/fimmu.2018.01378

45. Bunse T, Bunse L, Sahn F, Omokoko T, Stevanovic S, Av Deimling, Sahin U, Schmitz M, Wick W, Platten M (2018) Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat Med. https://doi.org/10.1038/s41591-018-0095-6

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.